Advertisement

Is a Twice Daily Dosage of Isosorbide-5-Mononitrate Sufficient in the Treatment of Stable Angina Pectoris?

  • O. J. Luurila
  • R. Kala
  • P. Hirvonen
  • A. Kohvakka
  • S. Sundberg
  • K. Lukkala
Part of the International Boehringer Mannheim Symposia book series (BOEHRINGER)

Abstract

Isosorbide-5-mononitrate (IS-5-MN) is the long-acting metabolite of isosorbide dinitrate. Oral IS-5-MN does not undergo first-pass metabolism and its bioavailability is almost 100%, which makes administration easier and more predictable [1]. It has been shown to exert antianginal effects both on acute and chronicc administration [2–4].

Keywords

Medication Period Daily Regimen Isosorbide Dinitrate Anginal Attack Nitrate Tolerance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abshagen U (1985) Pharmacokinetics of ISDN, sustained release ISDN and IS-5-MN. In: Cohn JN, Rittinghausen R (eds) Mononitrates. Springer-Verlag, Berlin Heidelberg New York, pp 53–66CrossRefGoogle Scholar
  2. 2.
    Müller G, Überbacher HJ, Glocke M (1985) Double-blind, randomized cross-over study on the coronary therapeutic efficacy and tolerance of IS-5-MN (ISMO 20) in a comparison with IS-5-MN + Metipranolol (ISMO-Disorat 20/5) and placebo. In: Cohn JN, Rittinghausen R (eds). Mononitrates. Springer-Verlag, Berlin Heidelberg New York, pp 221–229CrossRefGoogle Scholar
  3. 3.
    Schiavoni G, Montenero AF, Mazzari M, Biasucci LM and Manzoli U (1985) The efficacy of IS-5-MN in patients with ischemic heart disease: A pilot study. In: Mononitrates, International Boehringer Mannheim Symposia, eds. Cohn JN, Rittinghausen R, Montreaux, Switzerland, 230–234CrossRefGoogle Scholar
  4. 4.
    Rennhak U, Riebesel T and Biamino G (1985) A Double-Blind Cross-Over Study on the Effectiveness and Possible Development of Tolerance during Long-Term Therapy with Isosor-bide-5-Mononitrate or Isosorbide Dinitrate Slow-Release in Coronary Artery Disease. In: Mononitrates, International Boehringer Mannheim Symposia, eds. Cohn JN and Rittinghausen R, Montreaux, Switzerland, 147–153CrossRefGoogle Scholar
  5. 5.
    Parker JO (1985) Nitrate tolerance. Am J Cardiol 65: 281–311Google Scholar
  6. 6.
    Silber S, Krause KH, Theisen K and Jahrmärker H (1985) Nitrate tolerance: do “critical” plasma levels exist? Circulation II, 7: III-431 (1724)Google Scholar
  7. 7.
    Ohlmeier H, Mertens HM, Mannebach H and Gleichmann U (1985) Tolerance and Rebound Phenomena in Nitrate Therapy. In: Mononitrates, International Boehringer Mannheim Symposia, Eds. Cohn JN, Rittinghausen R, Montreaux, Switzerland, 107–123CrossRefGoogle Scholar
  8. 8.
    Jansen W, Tauchert M, Osterspey A and Hilger HH (1985) Comparison of the Hemodynamic Effects of Various Doses of Isosorbide-5-Mononitrate Following Single-Dose and Long-Term Administration in Patients with Coronary Heart Disease. In: Mononitrates, International Boehringer Mannheim Symposia, eds. Cohn JN, Rittinghausen R, Montreaux, Switzerland, 171–187CrossRefGoogle Scholar
  9. 9.
    Rudolph W, Blasini R, Reiniger G and Brügmann U (1983) Tolerance development during isosorbide dinitrate treatment: Can it be circumvented? Z Kardiol 72, Suppl 3, 195–198PubMedGoogle Scholar
  10. 10.
    Kala R, Hirvonen P, Gordin A, Sundberg S, Auvinen J and Halonen PI (1983) Nitroglycerin ointment effective for seven hours in severe angina pectoris. Acta Med Scand 213: 165–170PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • O. J. Luurila
  • R. Kala
  • P. Hirvonen
  • A. Kohvakka
  • S. Sundberg
  • K. Lukkala

There are no affiliations available

Personalised recommendations